Search Results
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
engineering enables longer half-life than Povetacicept (TACI vTD-Fc, the clinical dosing interval is once every 4 weeks.). It is well tolerated at 200 mg/kg in monkeys. Furthermore, high concentration formulation has been developed to facilitate subcutaneous administration. IBI3034
More news about: Innovent Biologics
Nov 04, 2025, 16:11 ET Match Group Announces Third Quarter Results
YuzuTM, Salams®, HERTM, and other smaller brands. Match Group Asia ("MG Asia") consists of the world-wide activity of the brands Pairs® and Azar®.
More news about: Match Group
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
we have extended the Phase 1 study to a 48 mg dose for a total of 8 weeks to evaluate longer-term early efficacy and patient exposure to DA-1726, while also exploring the non-titrated maximum tolerated dose. We expect to read out the results from the 48 mg cohort later this year."
More news about: MetaVia Inc.
Nov 04, 2025, 16:01 ET Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
announced the first patient was enrolled in the dose expansion phase of the study, where up to 40 patients will be randomized to either 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose for future clinical trials. Rigel
More news about: Rigel Pharmaceuticals, Inc.
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
rocatinlimab. ROCKET ASTRO a 52-week study of rocatinlimab is complete. This study evaluated two doses of rocatinlimab (150 mg and 300 mg) as monotherapy and in combination with background low-to-medium potency topical corticosteroids and/or topical calcineurin inhibitor therapy in
More news about: Amgen
Nov 04, 2025, 09:00 ET AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
treatment and for one month after the last dose of FOTIVDA. Allergic Reaction to Tartrazine: FOTIVDA 0.89 mg capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible patients.
More news about: AVEO, an LG Chem company
Nov 04, 2025, 08:30 ET Spinogenix Presents Topline Phase 2a Clinical Trial Results for SPG302, a First-in-Class ALS Treatment
SPG302 was well tolerated with no treatment-related serious adverse events over 6 months of oral daily dosing of 300mg Quantitative and objective biomarker evidence supported dose selection and a drug effect on brain areas impacted by ALS
More news about: Spinogenix
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
demonstrated: >95% B-cell clearance in humanized PBMC mouse models at doses as low as 0.01 mg/kg; >80% CAR expression across tissue-resident T cells with <1% off-target delivery to myeloid and hepatic
More news about: Grit Biotherapeutics Co., Ltd.
Nov 04, 2025, 08:00 ET Calliditas Therapeutics to Present at the American Society of Nephrology Kidney Week
/Kinpeygo® TARPEYO is an oral 4mg delayed-release formulation of budesonide, designed to dissolve in the pH of the distal ileum. Each capsule contains coated beads of budesonide that
More news about: Asahi Kasei Corporation
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Recent Industry Developments In August 2024, Takeda Pharmaceuticals launched NINLARO 0.5 mg capsules (ixazomib citrate) in Japan, expanding dosage flexibility for maintenance therapy in multiple myeloma. In August 2023, Janssen Biotech
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
doses (≥2.4 mg/kg).Patients with baseline brain metastases had an 83.3% (5/6) confirmed ORR at the 2.4 mg/kg dose and a 66.7% (12/18) confirmed ORR (1 pending confirmation) across all doses (≥2.4 mg/kg).6.7 month median PFS achieved across all lines and all doses (≥2.4 mg/kg); the median
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 09:42 ET JSPR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In JSPR To Contact Him Directly To Discuss Their Options
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Nov 03, 2025, 09:29 ET ATYR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATYR To Contact Him Directly To Discuss Their Options
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma
More news about: Faruqi & Faruqi, LLP
Nov 03, 2025, 09:15 ET CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B
efficacy, with a median follow-up time of 2.56 months (range: 0.9-5.9 months). For lymphodepletion, 6 patients received fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²), while 2 patients received a reduced lymphodepletion dose. Five patients achieved partial response (PR) or above: 3 achieved complete
More news about: CARsgen Therapeutics
Nov 03, 2025, 09:05 ET Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
date of April 28, 2025, six patients with previously treated chronic phase CML who had an atypical transcript received ELVN-001 at doses from 20 mg to 80 mg twice daily (BID) in the dose escalation phase of the ENABLE study. Testing for molecular response is non-standardized for atypical transcripts and
More news about: Enliven Therapeutics, Inc.
Nov 03, 2025, 09:05 ET Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
the 750 mg dose group. For evaluable transfusion dependent patients (≥16 weeks follow up) at dose levels of at least 500 mg QD and higher, 4/13 patients (31%) achieved durable red blood cell transfusion independence (RBC-TI) for >8 weeks (500 mg QD [1/3], 750 mg QD [2/5],
More news about: Rigel Pharmaceuticals, Inc.
Nov 03, 2025, 09:00 ET Apnimed Announces Publication in The Lancet of Positive Phase 2 Results Demonstrating Sulthiame's Efficacy in Obstructive Sleep Apnea
The FLOW study, a multicenter, randomized, double-blind, placebo-controlled, dose-finding trial, evaluated three dosages of sulthiame (100 mg, 200 mg, and 300 mg) administered once daily at bedtime for 15 weeks. The study enrolled 298 adult patients with untreated, moderate to severe OSA across 28 sites
More news about: Apnimed, Inc.
Nov 03, 2025, 09:00 ET Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
monotherapy, enzomenib was escalated from 40 mg twice a day (BID) to 400 mg BID with no dose-limiting toxicities (DLTs) in 116 patients with sustained complete remission (CR) and complete remission with partial hematologic recovery (CRh) seen at doses of 200, 300 and 400 mg BID. Given the wide therapeutic window
More news about: Sumitomo Pharma America
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment. LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules. Please see Prescribing Information for LENVIMA (lenvatinib) at
More news about: Eisai Inc.
Nov 03, 2025, 08:00 ET Orforgliprona, GLP-1 oral da Lilly, demonstra controle glicêmico superior em dois estudos bem-sucedidos de Fase 3, reconfirmando seu potencial como opção de tratamento do diabetes tipo 2
orforgliprona 3 mg, 12 mg e 36 mg com dapagliflozina 10 mg em participantes com diabetes tipo 2 e controle glicêmico inadequado em uso de metformina. O estudo randomizou 962 participantes em uma proporção de 1:1:1:1 para receber orforgliprona 3 mg, 12 mg ou 36 mg, ou dapagliflozina 10 mg uma vez ao dia,
More news about: Eli Lilly do Brasil
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
have undergone surgery as their only treatment. As of March 7, 2023, 331 patients were randomized globally to receive VORANIGO 40 mg daily (n=168) or placebo (n=163) continuously in 28-day cycles. Of the 331 patients, 172 had oligodendroglioma (88 VORANIGO; 84 placebo) and 159 patients
More news about: Servier Pharmaceuticals
Nov 03, 2025, 07:07 ET RED BULL REVEALS THE NEW RED BULL WINTER EDITION FUJI APPLE & GINGER
in 178 countries worldwide, and more than 12.6 billion cans of Red Bull were sold in 2024 alone. An 8.4 fl oz can of Red Bull Energy Drink contains 80 mg of caffeine, about the same as in a home-brewed cup of coffee. For more information, visit
More news about: Red Bull
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
NCT04562389) completed enrollment with 353 patients in early September 2025. SENTRY is evaluating 60 mg once-weekly selinexor in combination with ruxolitinib compared to ruxolitinib plus placebo. The preliminary baseline characteristics for patients enrolled
More news about: Karyopharm Therapeutics Inc.
Nov 01, 2025, 08:00 ET Semaglutida entra para o "hall da fama" da revista Time como uma das melhores invenções dos últimos 25 anos
conta atualmente com cerca de 2.500 funcionários e está presente com escritório corporativo em São Paulo (SP) e unidade de produção em Montes Claros (MG). Para mais informações, visite www.novonordisk.com.br e siga nossos perfis oficiais nas redes
More news about: NOVO NORDISK
Oct 31, 2025, 13:04 ET BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
group, n=556) at Week 48. Only patients who entered the third year are included.2-5 The approved dosing regimen is BIMZELX 320mg Q2W to Week 16 and then 320mg Q4W thereafter.1 Results included patients receiving both Q2W and Q4W after Week 48. Per protocol, all patients who continued
More news about: UCB